AZN vs. THC: A Head-to-Head Stock Comparison
UpdatedHere’s a clear look at AZN and THC, comparing key factors like performance, valuation metrics, dividends, and financial strength. It’s built for investors or anyone curious to see how these two stocks match up.
Company Overview
AZN dominates in value with a market cap of 432.07 billion USD, eclipsing THC’s 15.12 billion USD by roughly 28.57×.
THC carries a higher beta at 1.63, indicating it’s more sensitive to market moves, while AZN remains steadier at 0.18.
AZN trades as an ADR, giving U.S. investors a simple on-ramp to its foreign shares, while THC remains a standard domestic listing.
| Symbol | AZN | THC |
|---|---|---|
| Company Name | AstraZeneca PLC | Tenet Healthcare Corporation |
| Country | GB | US |
| Sector | Healthcare | Healthcare |
| Industry | Drug Manufacturers - General | Medical - Care Facilities |
| CEO | Mr. Pascal Claude Roland Soriot D.V.M., M.B.A. | Dr. Saumya Sutaria M.D. |
| Price | 69.68 USD | 162.83 USD |
| Market Cap | 432.07 billion USD | 15.12 billion USD |
| Beta | 0.18 | 1.63 |
| Exchange | NASDAQ | NYSE |
| IPO Date | May 12, 1993 | March 17, 1980 |
| ADR | Yes | No |
Performance Comparison
This chart compares the performance of AZN and THC over the past year by tracking the growth of an initial $10,000 investment in each (starting one year ago).
Hover over the lines to see the investment’s value and total return (%) at specific dates.
Data is adjusted for dividends and splits.
Valuation Metrics Comparison
For a detailed comparison of valuation metrics between AZN and THC, please refer to the table below.
| Symbol | AZN | THC |
|---|---|---|
| Price-to-Earnings Ratio (P/E, TTM) | 27.80 | 10.55 |
| Forward PEG Ratio (TTM) | 2.50 | 0.48 |
| Price-to-Sales Ratio (P/S, TTM) | 3.93 | 0.74 |
| Price-to-Book Ratio (P/B, TTM) | 5.26 | 3.67 |
| Price-to-Free Cash Flow Ratio (P/FCF, TTM) | 22.33 | 10.64 |
| EV-to-EBITDA (TTM) | 13.68 | 5.70 |
| EV-to-Sales (TTM) | 4.41 | 1.23 |
| EV-to-Free Cash Flow (TTM) | 25.07 | 17.79 |
Dividend Comparison
AZN delivers a 1.39% dividend yield, blending income with growth, whereas THC appears to retain its profits, possibly to fund operations, R&D, or other growth initiatives.
| Symbol | AZN | THC |
|---|---|---|
| Dividend Yield (TTM) | 1.39% | 0.00% |
Financial Strength Metrics Comparison
This section dives into the financial resilience of AZN and THC, spotlighting key metrics like liquidity, leverage, and debt coverage. Check out the standout observations below where notable differences or extremes pop up.
- AZN’s current ratio of 0.90 signals a possible liquidity squeeze, while THC at 1.78 comfortably covers its short-term obligations.
- AZN’s quick ratio of 0.70 suggests it may struggle to cover immediate liabilities without selling inventory or raising cash, whereas THC at 1.70 maintains a comfortable buffer of liquid assets.
- THC is highly leveraged (debt-to-equity ratio 3.15), elevating both potential gains and risks, compared to AZN at 0.77, which maintains a steadier capital structure.
| Symbol | AZN | THC |
|---|---|---|
| Current Ratio (TTM) | 0.90 | 1.78 |
| Quick Ratio (TTM) | 0.70 | 1.70 |
| Debt-to-Equity Ratio (TTM) | 0.77 | 3.15 |
| Debt-to-Assets Ratio (TTM) | 0.30 | 0.45 |
| Interest Coverage Ratio (TTM) | 7.95 | 5.80 |